Cite
HARVARD Citation
Handelsman, Y. et al. (2017). A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Current medical research and opinion. pp. 1861-1868. [Online].